Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11312923rdf:typepubmed:Citationlld:pubmed
pubmed-article:11312923lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0376607lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0935929lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0282774lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:11312923lifeskim:mentionsumls-concept:C0113556lld:lifeskim
pubmed-article:11312923pubmed:issue8lld:pubmed
pubmed-article:11312923pubmed:dateCreated2001-4-23lld:pubmed
pubmed-article:11312923pubmed:abstractText3-Guanidinopropionic acid (1) has been demonstrated both to improve insulin sensitivity and to promote weight loss selectively from adipose tissue in animal models of non-insulin-dependent diabetes mellitus (NIDDM). However, 1 has also been shown to be a substrate for both the creatine transporter and creatine kinase, leading to marked accumulation in muscle tissue as the corresponding N-phosphate. The corresponding aminoguanidine analogue 2 was recently discovered to retain the antidiabetic activity of 1 while being markedly less susceptible to creatine-like metabolism, suggesting that it should have less potential to accumulate in muscle. Further structural modification of 2 was undertaken to investigate whether the antidiabetic potency could be augmented while maintaining resistance to creatine-like metabolism. Modifications such as alpha-alkylation, homologation, and bioisosteric replacement of the aminoguanidine all were detrimental to antidiabetic activity. However, the simple regioisomeric aminoguanidinoacetic acid 9 and diaminoguanidinoacetic acid analogue 7 were found to be equipotent to 2, leading eventually to the discovery of the significantly more potent diaminoguanidinoacetic acid regioisomers 52 and 53. Further attempts to modify the more active template represented by 52 led only to reductions in antidiabetic activity. Each of the new active analogues displayed the same resistance to creatine-like metabolism as 2. Further testing of 7, 9, and 53 in obese diabetic ob/ob mice confirmed that weight loss is induced selectively from adipose tissue, similar to the lead 1. Administration of 53 to insulin-resistant rhesus monkeys led to reductions in both fasting and post-prandial plasma glucose levels with concomitant reductions in plasma insulin levels, suggesting that the compound improved the action of endogenous insulin. Compounds 7 and 53 were selected for further preclinical development.lld:pubmed
pubmed-article:11312923pubmed:languageenglld:pubmed
pubmed-article:11312923pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:citationSubsetIMlld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11312923pubmed:statusMEDLINElld:pubmed
pubmed-article:11312923pubmed:monthAprlld:pubmed
pubmed-article:11312923pubmed:issn0022-2623lld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:YuJ HJHlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:TuckerJ AJAlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:StevensF CFClld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:MayP DPDlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:TanisS PSPlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:BurnJ IJIlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:VidmarT JTJlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:EvansB RBRlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:CudahyM MMMlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:MeglassonM...lld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:RobinsonD DDDlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:LarsenS DSDlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:ConnellM AMAlld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:VaillancourtV...lld:pubmed
pubmed-article:11312923pubmed:authorpubmed-author:FisherP VPVlld:pubmed
pubmed-article:11312923pubmed:issnTypePrintlld:pubmed
pubmed-article:11312923pubmed:day12lld:pubmed
pubmed-article:11312923pubmed:volume44lld:pubmed
pubmed-article:11312923pubmed:ownerNLMlld:pubmed
pubmed-article:11312923pubmed:authorsCompleteYlld:pubmed
pubmed-article:11312923pubmed:pagination1231-48lld:pubmed
pubmed-article:11312923pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:meshHeadingpubmed-meshheading:11312923...lld:pubmed
pubmed-article:11312923pubmed:year2001lld:pubmed
pubmed-article:11312923pubmed:articleTitleSynthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid.lld:pubmed
pubmed-article:11312923pubmed:affiliationDepartments of Medicinal Chemistry, Pharmacology, and Research Biostatistics, Pharmacia Corporation, 301 Henrietta Street, Kalamazoo, Michigan 49007, USA. valerie.a.vaillancourt@am.pnu.comlld:pubmed
pubmed-article:11312923pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11312923pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11312923lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11312923lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11312923lld:pubmed